+252.7%
FCX vs GSK
+97.4%
+155.3%
-72.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -6.4% | -0.1% | -6.2% | -6.3% |
| 7D | -22.4% | -5.3% | -17.0% | -20.3% |
| 30D | -33.3% | -3.7% | -29.6% | -32.2% |
| 3M | -35.3% | -7.3% | -28.0% | -33.3% |
| 6M | -24.1% | -4.2% | -19.9% | -23.5% |
| YTD | -8.6% | +0.9% | -9.5% | -11.1% |
| 1Y | +17.1% | +7.3% | +9.9% | +10.3% |
| 3Y | +30.2% | +52.7% | -22.5% | -5.5% |
| 5Y | +28.7% | +40.1% | -11.4% | -3.7% |
| All | +252.7% | +97.4% | +155.3% | +125.4% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling